Novozymes A/S (VIE:NZYM)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.67B +6.1% |
| Revenue (ttm) | 4.30B +4.9% |
| Net Income | 631.60M +11.8% |
| EPS | 1.35 -32.0% |
| Shares Out | n/a |
| PE Ratio | 42.23 |
| Forward PE | 25.08 |
| Dividend | 0.88 (1.55%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | n/a |
| Open | 57.84 |
| Previous Close | 57.74 |
| Day's Range | 57.16 - 57.84 |
| 52-Week Range | 45.31 - 62.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Novozymes
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; e... [Read more]
Financial Performance
In 2025, Novozymes's revenue was 4.16 billion, an increase of 8.45% compared to the previous year's 3.83 billion. Earnings were 583.60 million, an increase of 90.84%.
Financial StatementsNews
Novonesis price target raised to DKK 540 from DKK 520 at JPMorgan
JPMorgan raised the firm’s price target on Novonesis (NVZMY) to DKK 540 from DKK 520 and keeps an Overweight rating on the shares. Over the past roughly 18 months, Novonesis…
Novonesis price target raised to DKK 500 from DKK 422 at Berenberg
Berenberg raised the firm’s price target on Novonesis (NVZMY) to DKK 500 from DKK 422 and keeps a Buy rating on the shares.
Novonesis price target raised to DKK 535 from DKK 520 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on Novonesis (NVZMY) to DKK 535 from DKK 520 and keeps an Overweight rating on the shares. Published first…
Novozymes Earnings Call Transcript: Q2 2026
Delivered 8% organic sales growth and improved margins in H1 2026, raising full-year guidance to 7%-8%. Growth was broad-based across all segments, with strong innovation, new product launches, and a €1 billion share buyback program announced.
Novozymes Quarterly report: Q2 2026
Novozymes has published its Q2 2026 quarterly earnings report on August 20, 2026.
Novozymes Slides: Q2 2026
Novozymes has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Novonesis price target raised to DKK 520 from DKK 500 at JPMorgan
JPMorgan analyst Chetan Udeshi raised the firm’s price target on Novonesis (NVZMY) to DKK 520 from DKK 500 and keeps an Overweight rating on the shares.
Novonesis upgraded to Neutral from Underperform at BNP Paribas
BNP Paribas upgraded Novonesis (NVZMY) to Neutral from Underperform with a price target of DKK 415, up from DKK 362. The firm cites valuation following the stock’s recent pullback for…
Novonesis price target raised to DKK 490 from DKK 480 at Deutsche Bank
Deutsche Bank analyst Virginie Boucher-Ferte raised the firm’s price target on Novonesis (NVZMY) to DKK 490 from DKK 480 and keeps a Buy rating on the shares. Published first on…
Novozymes Slides: Investor presentation
Novozymes has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Novonesis price target lowered to DKK 552 from DKK 560 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Novonesis (NVZMY) to DKK 552 from DKK 560 and keeps an Overweight rating on the shares.
Novonesis upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux analyst Patrick Roquas upgraded Novonesis (NVZMY) to Buy from Hold with a price target of DKK 460, up from DKK 390. The firm says the company has the…
Novonesis price target raised to DKK 440 from DKK 415 at Citi
Citi raised the firm’s price target on Novonesis (NVZMY) to DKK 440 from DKK 415 and keeps a Buy rating on the shares.
Novozymes Earnings Call Transcript: Q1 2026
Q1 2026 saw 7% organic sales growth, strong innovation, and margin resilience despite currency and input cost headwinds. Full-year guidance for 5%-7% organic growth and 37%-38% EBITDA margin is confirmed, with strategic investments supporting long-term targets.
Novozymes Quarterly report: Q1 2026
Novozymes has published its Q1 2026 quarterly earnings report on May 5, 2026.
Novozymes Slides: Q1 2026
Novozymes has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Novozymes Slides: Investor presentation
Novozymes has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
Novonesis price target lowered to DKK 500 from DKK 540 at JPMorgan
JPMorgan lowered the firm’s price target on Novonesis (NVZMY) to DKK 500 from DKK 540 and keeps an Overweight rating on the shares.
Novonesis upgraded to Buy from Neutral at Rothschild & Co Redburn
Rothschild & Co Redburn upgraded Novonesis (NVZMY) to Buy from Neutral with a DKK 445 price target
Novonesis upgraded to Buy from Sell at Citi
Citi analyst Ranulf Orr upgraded Novonesis (NVZMY) to Buy from Sell with a DKK 415 price target The firm cites the stock’s valuation reset combined with the company’s “more resilient”…
Novonesis price target lowered to DKK 410 from DKK 478 at Berenberg
Berenberg lowered the firm’s price target on Novonesis (NVZMY) to DKK 410 from DKK 478 and keeps a Buy rating on the shares.
Novozymes Earnings Call Transcript: Q4 2025
Organic sales grew 7% in 2025, with strong volume-driven growth across all segments and a 37.1% adjusted EBITDA margin, despite currency headwinds. 2026 guidance targets 5%-7% organic growth and continued margin expansion, supported by innovation, synergies, and capacity investments.
Novozymes Annual report: Q4 2025
Novozymes has published its Q4 2025 annual report on February 25, 2026.
Novozymes Slides: Q4 2025
Novozymes has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Novonesis price target lowered to DKK 540 from DKK 560 at JPMorgan
JPMorgan analyst Chetan Udeshi lowered the firm’s price target on Novonesis (NVZMY) to DKK 540 from DKK 560 and keeps an Overweight rating on the shares.